Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Daunorubicin is indicated in combination with cytarabine for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
- Associated Therapies
- -
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Phase 1
Completed
- Conditions
- Chronic Myelomonocytic LeukemiaPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in Transformation
- Interventions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00005942
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase 3
Completed
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- First Posted Date
- 2003-10-28
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 640
- Registration Number
- NCT00003190
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Phase 1
Completed
- Conditions
- Acute Undifferentiated LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaL1 Adult Acute Lymphoblastic LeukemiaL1 Childhood Acute Lymphoblastic LeukemiaL2 Adult Acute Lymphoblastic LeukemiaL2 Childhood Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia
- Interventions
- Drug: allopurinolDrug: cyclophosphamideDrug: daunorubicin hydrochlorideDrug: vincristine sulfateDrug: dexamethasoneDrug: asparaginaseBiological: filgrastimDrug: imatinib mesylateDrug: methotrexateDrug: cytarabineDrug: trimethoprim-sulfamethoxazoleDrug: mercaptopurineDrug: leucovorin calciumBiological: alemtuzumabDrug: acyclovirOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 302
- Registration Number
- NCT00061945
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
Phase 1
Completed
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 41
- Registration Number
- NCT00005793
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Phase 3
Completed
- Conditions
- Leukemia
- Interventions
- Biological: sargramostimDrug: busulfanProcedure: Allogeneic HCTDrug: cyclophosphamideDrug: cytarabineDrug: gemtuzumab ozogamicin (GO)Drug: DaunorubicinProcedure: Autologous HCT
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 657
- Registration Number
- NCT00049517
- Locations
- 🇺🇸
Community Medical Center, Missoula, Montana, United States
🇺🇸Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Phase 3
Completed
- Conditions
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Promyelocytic Leukemia (M3)Childhood Acute Promyelocytic Leukemia (M3)Untreated Adult Acute Myeloid LeukemiaUntreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 420
- Registration Number
- NCT00003934
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Phase 3
Completed
- Conditions
- Adult Acute Eosinophilic LeukemiaAdult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Basophilic LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Interventions
- Drug: cytarabineBiological: aldesleukinOther: clinical observationDrug: daunorubicin hydrochlorideBiological: filgrastimDrug: etoposideOther: pharmacological studyDrug: valspodarDrug: busulfanProcedure: autologous hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 720
- Registration Number
- NCT00006363
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Applicable
Completed
- Conditions
- T-cell Childhood Acute Lymphoblastic LeukemiaUntreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: prednisoneDrug: vincristine sulfateDrug: daunorubicin hydrochlorideDrug: asparaginaseDrug: methotrexateDrug: cyclophosphamideDrug: cytarabineDrug: mercaptopurineDrug: leucovorin calciumDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: thioguanineRadiation: radiation therapyDrug: pegaspargaseOther: pharmacological studyDrug: nelarabineOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00016302
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase 3
Completed
- Conditions
- Childhood Acute Erythroleukemia (M6)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Monoblastic Leukemia (M5a)Childhood Acute Monocytic Leukemia (M5b)Childhood Acute Myeloblastic Leukemia With Maturation (M2)Childhood Acute Myeloblastic Leukemia Without Maturation (M1)Childhood Acute Myelomonocytic Leukemia (M4)Childhood Myelodysplastic SyndromesChronic Myelomonocytic Leukemiade Novo Myelodysplastic Syndromes
- Interventions
- Drug: daunorubicin hydrochlorideDrug: asparaginaseDrug: therapeutic hydrocortisoneRadiation: 3-dimensional conformal radiation therapyDrug: fludarabine phosphateProcedure: allogeneic bone marrow transplantationBiological: filgrastimDrug: cytarabineDrug: idarubicinDrug: dexamethasoneBiological: aldesleukinDrug: thioguanineDrug: etoposideDrug: methotrexateDrug: cyclophosphamideDrug: busulfan
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 880
- Registration Number
- NCT00002798
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
Phase 3
Completed
- Conditions
- Recurrent Childhood Acute Lymphoblastic LeukemiaChildhood Acute Lymphoblastic Leukemia in Remission
- Interventions
- Biological: filgrastimDrug: asparaginaseDrug: cyclophosphamideDrug: cyclosporineDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: etoposideDrug: ifosfamideDrug: imatinib mesylateDrug: leucovorin calciumDrug: mercaptopurine tabletDrug: methotrexateDrug: pegaspargaseDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 220
- Registration Number
- NCT00022737
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath